TABLE 1.
Participant demographics
| Demographics |
Total in analysis, n (%) n = 120 |
Tested, n n = 28 |
Not tested, n n = 75 |
Unknown, n n = 17 |
Diagnosed before 2014 a , n n = 161 |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 29 (24.2) | 6 | 23 | – | 46 |
| Female | 90 (75.0) | 22 | 68 | – | 114 |
| Prefer not to share | 1 (0.8) | 0 | 1 | – | 1 |
| Year of diagnosis | |||||
| Before 2014 | 3 (2.5) | 3 | 161 | ||
| 2014–2018 | 66 (55.0) | 9 | 46 | 11 | n/a |
| 2019–2021 | 51 (42.5) | 16 | 29 | 6 | n/a |
| Did you have DecisionDx testing? | |||||
| Yes | 28 (23.3) | 1 | |||
| No | 75 (62.5) | 138 | |||
| Unsure | 17 (14.2) | 22 | |||
| Insurance coverage | |||||
| Commercial | 84 (70.0) | 22 | 55 | 7 | 109 |
| Commercial with MedAdvantage | 6 (5.0) | 2 | 4 | 0 | 1 |
| Medicare | 21 (17.5) | 3 | 12 | 6 | 37 |
| None | 1 (0.8) | 0 | 1 | 0 | 2 |
| I do not know/did not answer | 8(6.7) | 0 | 1 | 1 | 12 |
| Desired prognostic information about tumor | |||||
| Yes | 108 (90.0) | 27 | 67 | 14 | 134 |
| No | 7 (5.8) | 0 | 6 | 1 | 10 |
| Unsure | 5 (4.2) | 1 | 2 | 2 | 17 |
a
The 31‐GEP test became widely available in 2014. Therefore, we did not include patients who were diagnosed before this time and who did not state they received 31‐GEP (with additional responses) in the main analysis because the test would not likely have been available to these respondents.